TipRanks
Go Ultimate55% OFF

Andrew Last Insider Profile

11 Followers

Andrew Last, Director at Insight Molecular Diagnostics, holds 58.75K shares in Insight Molecular Diagnostics (Ticker: IMDX), holds 7.56K shares in Bio-Rad Laboratories (Ticker: BIO), holds 4.00K shares in Precigen (Ticker: PGEN).

Andrew Last's Trading History

IMDX
Insight Molecular Diagnostics
Jul 06, 2026DirectorUninformative Sell43.81K$173.91K
BIO
Bio-Rad Laboratories
Sep 10, 2024EVP & COOUninformative Buy897.72K$2.81M
PGEN
Precigen
Nov 15, 2017COOInformative Buy24.20K$27.76K
AFFX
Affymetrix
Apr 01, 2016―Uninformative Sell―$2.91M

You May Also Like

Andrew Last insider profile FAQ

What is the percentage of profitable transactions made by Andrew Last?
The percentage of profitable transactions made by Andrew Last is 33%.
What is the average return per transaction made by Andrew Last?
The average return per transaction made by Andrew Last is -24.60%.
What stocks does Andrew Last hold?
Andrew Last holds: IMDX, AFFX, BIO, PGEN stocks.
What was Andrew Last’s latest transaction?
Andrew Last’s latest transaction was an Uninformative Sell of $43.81K.
What was Andrew Last's most profitable transaction?
Andrew Last’s most profitable transaction was an Informative Sell of BIO stock on September 3, 2021. The return on the trade was 41.60%.
What is Andrew Last's role in Insight Molecular Diagnostics?
Andrew Last's role in Insight Molecular Diagnostics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.